What are the gross and operating margins for each product line in this quarter? | ASC (Aug 07, 2025) | Candlesense
ASC

What are the gross and operating margins for each product line in this quarter?

Answer

The news release you provided only includes the Q2 2025 revenue figures for Ascendis Pharma’s two product lines:

  • YORVIPATH®: €103.0 million
  • SKYTROFA®: €50.7 million

It does not disclose any information about gross margins, operating margins, or any other profitability metrics for either product line. Consequently, based solely on the content you shared, I cannot calculate or report the gross or operating margins for YORVIPATH® or SKYTROFA® for this quarter.

If you have access to a more detailed earnings release (e.g., a full financial statement, a management discussion & analysis, or a supplemental filing) that includes cost of goods sold, operating expenses, or margin percentages, please provide that excerpt and I’ll be happy to compute the margins for you. Otherwise, you may need to consult Ascendis Pharma’s investor relations website or the full SEC/ESMA filing for Q2 2025 to obtain the missing margin data.

Other Questions About This News

Are there any notable changes in market share for YORVIPATH® or SKYTROFA® versus competitors? How does ASC's Q2 performance compare to peer companies in the same therapeutic area? How might the earnings results affect the short‑term price momentum and trading volume? Is there any information on the pipeline or upcoming regulatory milestones that could influence future earnings? What are the key drivers behind the revenue performance—price changes, volume growth, or new product launches? What is the impact of these results on the valuation multiples (e.g., P/E, EV/Revenue) for ASC? Did the company provide any guidance or outlook for H2 2025 or FY 2025? How does the Q2 2025 revenue compare to the company's consensus estimates? What is the year‑over‑year growth rate for YORVIPATH® and SKYTROFA® revenues?